Guardant Health, Inc. (GH) Stock: Price, Forecast & Analyst Target
Guardant Health, Inc. (GH) — MoonshotScore 34/100 (Weak band), calculated Nov 18, 2026. Price $145.14 (+1.30%), as of the Nov 18, 2026 trading session; market cap $19.6B.
Educational signal · not a buy or sell recommendation · How to read this
Guardant Health, Inc. · GH · NASDAQ · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Guardant Health sells liquid-biopsy and tissue-based oncology tests, cancer screening, clinical-genomic analytics and development services for biopharma customers. Revenue is expanding quickly, but screening investment and rising operating expense still keep cash flow negative; durability depends on closing that gap without exhausting the balance-sheet cushion.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Guardant Health (GH)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A strained balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $265M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z 3.38 · Piotroski F 3
Holding back: balance-sheet strain
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 33 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak | |
| 34 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $145.14 | |
| Change on the day | +1.30% | |
| 52-week range | $74.55–$191.05 | |
| Market capitalisation | $19.6B | — |
| Price / earnings (trailing) | -243.47 | |
| Shares traded on the day | 1.50M | |
| Beta (volatility vs the S&P 500) | 1.66 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Guardant Health (GH): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Guardant Health (GH), and what does it report?
Short answer · as of
Guardant is a precision-oncology platform rather than a developer of cancer medicines.
Research dated 2026-09-12.
It earns revenue from testing patients with advanced or early-stage cancer, screening asymptomatic people, supplying clinical-genomic analytics, and supporting biopharma customers with companion diagnostics and clinical development services.
Reported revenue primarily reflects Oncology, Biopharma & Data, and the emerging Screening business, with licensing and other activity contributing little. Oncology remains the commercial base, while Screening and data services expose the company to distinct adoption cycles and spending requirements.
What do the latest results show for Guardant Health (GH)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $265M.
Research dated 2026-09-12.
The latest quarter extended the revenue climb across the displayed history, and gross profit rose with it. Operating and net losses nevertheless widened from the preceding period as selling and administrative expense climbed and research spending remained heavy. Revenue has also cleared consensus throughout the earnings history shown, while per-share results have been uneven.
Management’s outlook calls for further expense growth, says the business outside Screening should generate positive free cash flow, and retains a companywide cash-flow breakeven goal. That framing identifies Screening as the principal bridge between strong commercial momentum and the intended cash profile.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $265M | -$93M | -$0.74 (diluted) |
| Q4 FY2025 | $281M | -$128M | -$1.00 (diluted) |
| Q1 FY2026 | $302M | -$112M | -$0.85 (diluted) |
| Q2 FY2026 | $335M | -$120M | -$0.90 (diluted) |
What are the financial strengths and risks for Guardant Health (GH)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cash and investments provide substantial operating runway at the recent pace of cash use, and near-term liquidity ratios remain strong. The company is not in a net-cash position, however: debt exceeds cash and short-term investments, while operations and capital spending continue to consume cash.
Management’s carve-out of Screening from expected positive free cash flow makes that business the visible funding burden. If commercial growth slows while selling expense remains elevated, persistent losses could continue despite healthy gross margins and ample liquidity.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
What should you watch next at Guardant Health (GH)?
Short answer · as of
Current published price targets run low $180.00 · high $225.00 · consensus $203.40 · median $200.00 against a quoted price of $145.14 (as of Nov 18, 2026).
Research dated 2026-09-12.
Consensus expects another revenue step-up and a much smaller per-share loss at the scheduled earnings release. Delivery on revenue without a corresponding improvement in operating loss or cash use would repeat the pattern already visible in recent results.
Reveal Ultra provides the near-term product marker. Launch progress and continued Reveal momentum should be read alongside segment mix and cash generation: Screening must become less burdensome while Oncology and Biopharma & Data sustain the commercial base.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q3 FY2025) was filed Oct 29, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Guardant Health compare with its peers?
Short answer
Guardant Health's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Guardant combines advanced-cancer liquid biopsy, residual-disease testing, cancer screening and biopharma analytics built around a clinical-genomic dataset. Unlike a drug developer, it sells tests, datasets and development support rather than depending on sales of a therapy.
Compared with a testing-only laboratory, GuardantINFORM and companion-diagnostic services make biopharma research clients part of the model. That breadth creates distinct routes to adoption, but it also requires concurrent spending across established oncology products and the newer Screening business.
| Company | Price | Market value | Score |
|---|---|---|---|
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $1737.26 Nov 18, 2026 | $34.6B | 93 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $49.56 Nov 18, 2026 | $10.2B | 83 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| $195.16 Nov 18, 2026 | $14.6B | 73 5-pillar Nov 18, 2026 | |
| $152.43 Nov 18, 2026 | $17.0B | 71 5-pillar Nov 18, 2026 | |
| $370.78 Nov 18, 2026 | $30.1B | 71 5-pillar Nov 18, 2026 | |
| $333.25 Nov 18, 2026 | $16.0B | 70 5-pillar Nov 18, 2026 | |
| $86.48 Nov 18, 2026 | $14.7B | 66 5-pillar Nov 18, 2026 | |
| $289.50 Nov 18, 2026 | $42.0B | 36 5-pillar Nov 18, 2026 | |
| Guardant Health (GH) — this page | $145.14 | $19.6B | 34 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $180.00 – $225.00
- Consensus target
- $203.40
- Median target
- $200.00
Consensus record · Captured .
Measured against a quoted price of $145.14 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 58
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 2
- Other transactions
- 56
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GH in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 0.62% | $108.30M | Added +19.9% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Guardant Health (GH)?
- Guardant Health (GH) Stock Looks Richly Priced After Its Big Run
- Guardant Health Launches Guardant Reveal® Ultra for MRD Testing
- Guardant Health Insider Sold Shares Worth $547,149, According to a Recent SEC Filing
- Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing
What Investors Ask About Guardant Health (GH) — Healthcare
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Reveal Ultra add to Guardant Health’s residual-disease strategy?
Management presents Reveal Ultra as a more sensitive tumor-informed residual-disease test and pairs its planned launch with continued commercial momentum for Reveal. Its importance lies in adoption within early-stage cancer care, rather than merely expanding the advanced-cancer assay menu.
Why does Screening matter so much to Guardant Health’s cash burn?
Management expects the business outside Screening to generate positive free cash flow while consolidated operations remain cash-consuming. That carve-out makes Screening the key funding burden to track as revenue scales.
What does GuardantINFORM sell to biopharma customers?
GuardantINFORM turns the company’s clinical-genomic liquid-biopsy dataset into an in-silico research platform. It extends the business from processing patient tests into supplying analytical utility to research and clinical clients.
Why have Guardant Health’s revenue beats not produced profits?
Revenue has repeatedly exceeded estimates, but selling, administrative and research spending remain above gross profit, leaving operating and net results negative. The widening latest loss shows that top-line momentum has not yet delivered operating leverage.
What is the GH stock price today?
The last price recorded for Guardant Health, Inc. (GH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GH price target?
The analyst consensus price target for Guardant Health, Inc. (GH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold GH
Funds in our ETF coverage that list GH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Global X - Genomics & Biotechnology ETF (GNOM) | 4.71% |